Repeat transurethral resection of bladder tumor (TURBT) prior to radical cystectomy (RC) does not improve survival in cT2N0 muscle-invasive bladder cancer, according to a study published in The Journal of Urology.
In a propensity-score matched analysis of 548 patients, recurrence-free survival and overall survival did not differ significantly between groups receiving and not receiving repeat TURBT before RC.
The patients were matched by age, gender, receipt of neoadjuvant chemotherapy, preoperative hydronephrosis, variant histology, lymphovascular invasion, and carcinoma in situ.
The absence of residual tumor on repeat TURBT pathology was associated with improved recurrence-free survival and overall survival. However, more than 60% of patients with pT0 disease on repeat TURBT had residual disease on RC pathology, including 18% with extravesical disease.
“These data suggest that current clinical staging is an unreliable indicator of the extent of true residual disease,” the study authors wrote.
Bree KK, Kokorovic A, Westerman ME, et al. Repeat transurethral resection of muscle-invasive bladder cancer prior to radical cystectomy is prognostic but not therapeutic. J Urol. Published October 11, 2022. doi:10.1097/JU.0000000000003015
This article originally appeared on Renal and Urology News